Vertex Pharmaceuticals Stock Price To Earning

VRTX Stock

USD 450.37 0.86 0.19%

Vertex Pharmaceuticals fundamentals help investors to digest information that contributes to Vertex Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Vertex Stock. The fundamental analysis module provides a way to measure Vertex Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vertex Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Vertex Pharmaceuticals Company Price To Earning Analysis

Vertex Pharmaceuticals' Price to Earnings ratio is typically used for current valuation of a company and is one of the most popular ratios that investors monitor daily. Holding a low PE stock is less risky because when a company's profitability falls, it is likely that earnings will also go down as well. In other words, if you start from a lower position, your downside risk is limited. There are also some investors who believe that low Price to Earnings ratio reflects the low pricing because a given company is in trouble. On the other hand, a higher PE ratio means that investors are paying more for each unit of profit.

P/E

Market Value Per Share

Earnings Per Share

More About Price To Earning | All Equity Analysis

Current Vertex Pharmaceuticals Price To Earning

24.57 X

Most of Vertex Pharmaceuticals' fundamental indicators, such as Price To Earning, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vertex Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Vertex Price To Earning Driver Correlations

Understanding the fundamental principles of building solid financial models for Vertex Pharmaceuticals is extremely important. It helps to project a fair market value of Vertex Stock properly, considering its historical fundamentals such as Price To Earning. Since Vertex Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vertex Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vertex Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Short Term Debt	Accounts Payable	Net Receivables	Common Stock	Long Term Debt	Short Term Investments	Property Plant Equipment	Current Deferred Revenue	Good Will	Intangible Assets	Net Tangible Assets	Long Term Debt Total	Capital Surpluse	Deferred Long Term Liab	Short Long Term Debt	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		1.0	-0.98	0.94	0.99	1.0	-0.07	0.98	0.99	0.37	0.04	0.23	0.93	0.2	0.83	0.44	0.99	0.08	0.66	-0.55	0.78	0.79	0.93	0.92	0.78
Total Stockholder Equity	1.0		-0.98	0.95	0.98	1.0	-0.08	0.97	0.99	0.35	0.01	0.22	0.92	0.21	0.84	0.44	1.0	0.06	0.66	-0.56	0.79	0.79	0.94	0.92	0.78
Net Debt	-0.98	-0.98		-0.94	-0.96	-0.99	0.1	-0.95	-0.99	-0.34	0.0	-0.13	-0.89	-0.24	-0.84	-0.45	-0.99	0.02	-0.66	0.55	-0.79	-0.68	-0.96	-0.97	-0.69
Retained Earnings	0.94	0.95	-0.94		0.89	0.94	-0.07	0.93	0.93	0.07	-0.14	0.12	0.79	0.1	0.76	0.58	0.94	-0.07	0.44	-0.35	0.63	0.81	0.9	0.89	0.79
Total Liab	0.99	0.98	-0.96	0.89		0.99	-0.02	0.98	0.98	0.47	0.12	0.27	0.94	0.19	0.81	0.43	0.97	0.17	0.68	-0.55	0.78	0.78	0.91	0.9	0.76
Total Current Assets	1.0	1.0	-0.99	0.94	0.99		-0.08	0.98	0.99	0.37	0.03	0.21	0.93	0.21	0.83	0.44	1.0	0.07	0.65	-0.56	0.78	0.76	0.94	0.94	0.75
Short Term Debt	-0.07	-0.08	0.1	-0.07	-0.02	-0.08		0.02	-0.07	0.02	-0.13	-0.3	-0.03	-0.15	-0.28	0.12	-0.1	-0.05	-0.2	0.24	-0.17	0.09	-0.11	-0.11	0.03
Accounts Payable	0.98	0.97	-0.95	0.93	0.98	0.98	0.02		0.96	0.38	0.1	0.23	0.92	0.18	0.72	0.47	0.96	0.18	0.57	-0.46	0.69	0.82	0.9	0.89	0.8
Net Receivables	0.99	0.99	-0.99	0.93	0.98	0.99	-0.07	0.96		0.37	0.02	0.18	0.91	0.22	0.86	0.45	0.99	0.03	0.67	-0.55	0.8	0.72	0.94	0.94	0.71
Common Stock	0.37	0.35	-0.34	0.07	0.47	0.37	0.02	0.38	0.37		0.6	0.51	0.56	0.28	0.34	-0.1	0.36	0.42	0.72	-0.61	0.48	0.13	0.4	0.38	0.23
Long Term Debt	0.04	0.01	0.0	-0.14	0.12	0.03	-0.13	0.1	0.02	0.6		0.41	0.21	-0.05	0.02	-0.1	0.01	0.87	0.31	-0.23	0.0	-0.04	0.11	0.09	0.06
Short Term Investments	0.23	0.22	-0.13	0.12	0.27	0.21	-0.3	0.23	0.18	0.51	0.41		0.28	-0.06	0.29	0.02	0.21	0.34	0.21	-0.25	0.09	0.25	0.22	0.17	0.27
Property Plant Equipment	0.93	0.92	-0.89	0.79	0.94	0.93	-0.03	0.92	0.91	0.56	0.21	0.28		0.2	0.73	0.16	0.93	0.29	0.77	-0.75	0.79	0.73	0.84	0.83	0.72
Current Deferred Revenue	0.2	0.21	-0.24	0.1	0.19	0.21	-0.15	0.18	0.22	0.28	-0.05	-0.06	0.2		0.06	-0.2	0.25	-0.14	0.43	-0.34	0.55	0.03	0.21	0.18	0.04
Good Will	0.83	0.84	-0.84	0.76	0.81	0.83	-0.28	0.72	0.86	0.34	0.02	0.29	0.73	0.06		0.4	0.83	-0.07	0.68	-0.55	0.76	0.49	0.83	0.81	0.5
Intangible Assets	0.44	0.44	-0.45	0.58	0.43	0.44	0.12	0.47	0.45	-0.1	-0.1	0.02	0.16	-0.2	0.4		0.4	-0.23	-0.06	0.41	0.07	0.41	0.54	0.54	0.5
Net Tangible Assets	0.99	1.0	-0.99	0.94	0.97	1.0	-0.1	0.96	0.99	0.36	0.01	0.21	0.93	0.25	0.83	0.4		0.05	0.68	-0.59	0.8	0.76	0.94	0.93	0.75
Long Term Debt Total	0.08	0.06	0.02	-0.07	0.17	0.07	-0.05	0.18	0.03	0.42	0.87	0.34	0.29	-0.14	-0.07	-0.23	0.05		0.18	-0.22	-0.05	0.19	-0.01	-0.02	0.16
Capital Surpluse	0.66	0.66	-0.66	0.44	0.68	0.65	-0.2	0.57	0.67	0.72	0.31	0.21	0.77	0.43	0.68	-0.06	0.68	0.18		-0.86	0.88	0.37	0.68	0.64	0.47
Deferred Long Term Liab	-0.55	-0.56	0.55	-0.35	-0.55	-0.56	0.24	-0.46	-0.55	-0.61	-0.23	-0.25	-0.75	-0.34	-0.55	0.41	-0.59	-0.22	-0.86		-0.73	-0.28	-0.52	-0.5	-0.3
Short Long Term Debt	0.78	0.79	-0.79	0.63	0.78	0.78	-0.17	0.69	0.8	0.48	0.0	0.09	0.79	0.55	0.76	0.07	0.8	-0.05	0.88	-0.73		0.48	0.73	0.7	0.49
Long Term Investments	0.79	0.79	-0.68	0.81	0.78	0.76	0.09	0.82	0.72	0.13	-0.04	0.25	0.73	0.03	0.49	0.41	0.76	0.19	0.37	-0.28	0.48		0.65	0.59	0.95
Net Invested Capital	0.93	0.94	-0.96	0.9	0.91	0.94	-0.11	0.9	0.94	0.4	0.11	0.22	0.84	0.21	0.83	0.54	0.94	-0.01	0.68	-0.52	0.73	0.65		0.99	0.73
Net Working Capital	0.92	0.92	-0.97	0.89	0.9	0.94	-0.11	0.89	0.94	0.38	0.09	0.17	0.83	0.18	0.81	0.54	0.93	-0.02	0.64	-0.5	0.7	0.59	0.99		0.66
Capital Stock	0.78	0.78	-0.69	0.79	0.76	0.75	0.03	0.8	0.71	0.23	0.06	0.27	0.72	0.04	0.5	0.5	0.75	0.16	0.47	-0.3	0.49	0.95	0.73	0.66

Click cells to compare fundamentals

Generally speaking, the Price to Earnings ratio gives investors an idea of what the market is willing to pay for the company's current earnings.

Competition

Predict Vertex Pharmaceuticals

Vertex Retained Earnings

Retained Earnings

10.65 Billion

At this time, Vertex Pharmaceuticals' Retained Earnings are fairly stable compared to the past year.

Based on the latest financial disclosure, Vertex Pharmaceuticals has a Price To Earning of 24.57 times. This is 4.91% lower than that of the Biotechnology sector and notably higher than that of the Health Care industry. The price to earning for all United States stocks is 14.45% higher than that of the company.

Did you try this?

Run Companies Directory Now

Companies Directory

Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals

All Next

Launch Module

Vertex Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vertex Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vertex Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Vertex Fundamentals

	Return On Equity	-0.0298
	Return On Asset	0.12
	Profit Margin	(0.05) %
	Operating Margin	0.41 %
	Current Valuation	111.38 B
	Shares Outstanding	257.53 M
	Shares Owned By Insiders	0.07 %
	Shares Owned By Institutions	96.00 %
	Number Of Shares Shorted	4.5 M
	Price To Earning	24.57 X
	Price To Book	7.43 X
	Price To Sales	10.94 X
	Revenue	9.87 B
	Gross Profit	5.32 B
	EBITDA	4.61 B
	Net Income	3.62 B
	Cash And Equivalents	9.77 B
	Cash Per Share	38.06 X
	Total Debt	808.4 M
	Debt To Equity	0.06 %
	Current Ratio	4.70 X
	Book Value Per Share	60.65 X
	Cash Flow From Operations	3.54 B
	Short Ratio	4.51 X
	Earnings Per Share	(1.90) X
	Price To Earnings To Growth	1.18 X
	Target Price	513.87
	Number Of Employees	5.4 K
	Beta	0.39
	Market Capitalization	116.2 B
	Total Asset	22.73 B
	Retained Earnings	10.14 B
	Working Capital	10.6 B
	Current Asset	1.41 B
	Current Liabilities	506.35 M
	Net Asset	22.73 B

About Vertex Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Vertex Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GOOG	Alphabet Inc Class C
CRM	Salesforce

Additional Tools for Vertex Stock Analysis

When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC